BioVie Inc. (BIVI)
NASDAQ (CM) NASDAQ (CM) Primary Summary
BioVie advances Parkinson's Phase 3 development program with FDA engagement
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson's disease clinical development experts to finalize the design of a Phase 3 trial.
BioVie completes final patient visit in Phase 2 Long COVID trial
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases.
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
BioVie Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $1.9 | $1.75 | -$0.15 | -7.89% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 3 | $5.7 | $5.23 | -$0.47 | -8.25% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 14 | $25.21 | $22.61 | -$2.6 | -10.31% |
 Yuen Man Lee Persistent Asset Partners Ltd. | 14,996 | $29,092 | $23,393.76 | -$5,698.24 | -19.59% |
BioVie Inc. (BIVI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioVie Inc. ever had a stock split?
BioVie Inc. Profile
| Biotechnology Industry | Healthcare Sector | Cuong Viet Do CEO | NASDAQ (CM) Exchange | 09074F504 CUSIP |
| US Country | 13 Employees | - Last Dividend | 7 Jul 2025 Last Split | - IPO Date |
Overview
BioVie Inc. is a clinical stage biopharmaceutical company, operating predominantly within the United States, dedicated to the discovery, development, and eventual commercialization of novel pharmaceutical solutions aimed at treating chronic debilitating conditions. The company, which was initially known as NanoAntibiotics, Inc., underwent a name change to BioVie Inc. in July 2016, marking a significant milestone in its corporate journey since its inception in 2013. With its headquarters located in Carson City, Nevada, BioVie is at the forefront of addressing some of the most pressing medical challenges of the current era through its elaborate pipeline of groundbreaking drugs.
Products and Services
BIV201: This pivotal product has successfully completed a Phase IIa clinical trial and represents BioVie's ambitious efforts in tackling ascites caused by chronic liver cirrhosis. Ascites, an accumulation of fluid in the peritoneal cavity, often signifies advanced liver disease and poses significant treatment challenges. BIV201's progress through the clinical trial phases underscores its potential as a much-needed solution for patients grappling with this debilitating condition.
NE3107: An innovative therapeutic candidate, NE3107 targets the inflammatory extracellular single-regulated kinase pathway, potentially offering relief to patients suffering from neurological disorders. This compound is making strides in the clinical evaluation process, currently undergoing a Phase III clinical trial for the treatment of mild to moderate Alzheimer's disease. Alzheimer's, a progressive neurodegenerative disorder, significantly impacts cognitive function, whereas Parkinson’s disease, another focus of NE3107’s development in a separate Phase 2 clinical trial, affects movement. The dual focus on these distinct yet somewhat related neurological conditions marks NE3107 as a versatile component in BioVie’s product pipeline.
